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Abstract
The B subunit of cholera toxin (CTB) has been used as adjuvant to improve oral vaccine delivery
in type 1 diabetes. The effect of CTB/peptide formulations on antigen-specific CD4 T cells has
remained largely unexplored. We investigated by tetramer analysis how oral delivery of CTB
fused to 2 CD4 T cell epitopes, the BDC-2.5 T cell 2.5mi mimotope and glutamic acid
decarboxylase (GAD) 286–300, affected diabetogenic CD4 T cells in NOD mice. CTB-2.5mi
activated 2.5mi+ T cells when administered intraperitoneally and generated Ag-specific Foxp3+
Treg and Th2 cells following intragastric delivery. While 2.5mi+ and GAD-specific T cells were
tolerized in diabetes resistant NODxB6.Foxp3EGFP F1 and NOR mice, this did not occur in NOD
mice. This indicated NOD mice had a recessive genetic resistance to induce oral tolerance to both
CTB-fused epitopes. Contrarily to NODxB6.Foxp3EGFP F1 mice, oral treatment in NOD mice
lead to strong 2.5mi+ T cell activation and the sequestration of these cells to the effector-memory
pool. Oral treatment of NOD mice with CTB-2.5mi failed to prevent diabetes. These findings
underline the importance of investigating the effect of oral vaccine formulations on diabetogenic T
cells as in selected cases they may have counterproductive consequences in human patients.
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The induction of peripheral tolerance is the principal strategy of clinical and preclinical trials
in order to battle against autoimmune diseases. Amongst many approaches, oral tolerance
induction stands out as the method of choice as it is the least invasive method and therefore
has a high potential to find wide acceptance in patients. In the past, a series of adjuvants
have been used in order to increase oral vaccine delivery with the goal to minimize dosage
of antigen. One of them, the subunit B of cholera toxin (CTB), has been shown to efficiently
support the transmucosal transport of covalently linked protein by binding to its receptor, the
monosialoganglioside GM1 [1].
Several approaches have been used to apply CTB for the design of oral vaccines to prevent
type 1 diabetes (T1D). T1D is a result of the selective and progressive destruction of
pancreatic, insulin-producing beta cells by autoreactive T cells [2]. The non-obese diabetic
(NOD) mouse is a non-induced animal model that develops T1D with pathology similar to
the human disease [3]. In this model, prevention of T1D by oral administration of CTB
fusion proteins, conjugates, unconjugated adjuvant or included in recombinant vaccinia
viruses using different autoantigens such as insulin and glutamic acid decarboxylase has
been reported [4–8]. CTB as fusion protein or for conjugation has been generated in several
systems including bacteria [9], silk worms [10] or plants [11]. In the vast majority of reports,
no detailed T cell analyses were conducted, if at all. Disease prevention by transfer studies
into lymphocyte deficient NOD.scid mice was traced to the generation of either regulatory T
cells, a shift of a Th1 to a Th2 response, or both [4, 5]. However, in most documented
attempts, prevention of T1D by orally administered CTB-fusion proteins has remained only
partial. So far, no clinical trial in humans using any sort of oral vaccine has shown to
provide solid protection against the disease [12]. Although CTB has been found to be a safe
adjuvant in humans [13], in T1D prevention trials this adjuvant has not yet been used, most
likely because detailed reports on the fate of Ag-specifc T cells following oral treatment
with CTB-conjugate vaccines are still at large in relevant animal models.
In order to trace antigen-specific autoreactive T cells in the NOD mouse, we have previously
generated Ag7-based MHC class II tetramers using a strong agonist peptide mimotope,
2.5mi, that reliably stain the diabetogenic T cell clone BDC-2.5 [14] as well as a natural T
cell population in NOD mice, termed by us 2.5mi+ T cells [15, 16]. This T cell population is
generated early in life, expands during T1D pathogenesis and infiltrates pancreatic islets.
We previously explored to which degree manipulation of these cells by a DNA vaccination
approach designed to target the 2.5 mimotope to the MCH class II loading compartment
might induce general tolerance in NOD mice. Diabetes onset was delayed and partially
reduced, demonstrating that appropriate delivery of the 2.5 mimotope can induce T1D
protection in this model [17].
In light of these studies and in order to provide further mechanistic insights into oral
tolerance induction in the NOD mouse model, we wondered whether a different formulation
and application route of the 2.5 mimotope might improve tolerance. In the present report, we
fused the mimotope to CTB and applied it to prediabetic mice intragastrically. Treatment led
to the generation of Ag-specific Foxp3+ Treg and the secretion of the Th2 cytokine IL-4.
Unexpectedly however, in vivo parenteral challenge with the mimotope after oral treatment
revealed that while 2.5mi+ T cells were tolerized in diabetes resistant NODxB6 F1 and NOR
mice, this did not occur in the disease susceptible NOD mouse strain. These findings were
not limited to the mimotope but also extended to the glutamic acid decarboxylase (GAD)
derived peptide 286–300. Indeed, contrarily to the tolerogenic effect observed in diabetes
resistant control strains, oral treatment in NOD mice leads to strong T cell activation and the
sequestration of 2.5mi+ T cells to the effector-memory T cell pool. As a consequence,
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diabetes was not prevented by this fusion protein. Therefore, our study uncovers a recessive
impairment in the generation of oral tolerance in the NOD mouse when CTB is used as
adjuvant, at least in combination with selected antigens such as the strong agonist 2.5
mimotope peptide or the GAD-derived peptide, but instead leads to T cell activation. These
findings should have important consequences when planning equivalent vaccine
formulations for clinical trials to combat the human disease.
RESEARCH DESIGN AND METHODS
Reagents and cells
Abs were purchased from Biolegend (La Jolla, CA, USA) or Beckton Dickinson (Franklin
Lakes, NJ, USA), and cell culture media from Lonza (Barcelona, Spain). Streptavidin-PE
was obtained from Columbia Bioscience (Columbia, MD, USA). cDNAs for positive
interleukin PCR controls were purchased from Thermo Scientific (Epsom, UK). The
BDC-2.5 T cell hybridoma was generously provided to us by Dr. K. Haskins (University of
Colorado). Unless otherwise mentioned, all other reagents were obtained from Fluka or
Sigma (Madrid, Spain).
Mouse strains
NOD/LtJ and B6.Foxp3EGFP mice [18] were originally purchased from The Jackson
Laboratory (Bar Harbor, Maine, USA) and further bred in our special pathogen-free animal
facility (Parc Cientific Barcelona, Spain). NOD/LtJxB6.Foxp3EGFP F1 mice were bred in-
house. The T1D resistant NOR control strain has been previously described [19]. NOD
versus NOR experimental comparisons were carried out at The Jackson Laboratory.
NOD.Foxp3EGFP mice were generated in-house using a speed congenic approach by
backcrossing NOD/LtJxB6.Foxp3EGFP F1 animals into the NOD background while
monitoring 15 independent Idd loci. Mice homozygous after 4 generations for all NOD Idd
loci were further backcrossed for 2 generations with NOD mice and then intercrossed to
generate homozygous NOD.Foxp3EGFP (F6) animals.
Generation of recombinant proteins
The mature peptide of the subunit B from cholera toxin (amino acids T11-N124, Genbank
access number X58785) was PCR amplified from Vibrio cholerae (Spanish Tissue
Collection Type CECT 569) and subcloned into pET28a in between a vector-encoded 5′
met-val sequence and a 3′ sequence coding for a 9 aa linker ASGPGPGMV (linker 1),
followed by a hexa-histidine tag and a C-terminal GS sequence. To generate CTB-2.5mi and
CTB-GAD286–300 [20], the construct was further modified by introducing the 2.5mi peptide
AHHPIWARMDA or GAD286–300 followed by a second, 6 aa linker GLDPGM in-between
linker 1 and the hexahistidine tag (Fig. 1 A and supplemental Fig. S1 A). The proteins were
expressed in E. coli BL21 and purified and refolded from inclusion bodies using a published
protocol [21].
Soluble Ag7 MHC molecules complexed to the 2.5mi, GAD286–300 or the GPI control
peptide were expressed in D. melanogaster derived SC2 cells, purified and used for the
generation of tetramers as published [15, 22, 23].
In vitro T cell stimulation and cytokine analysis by ELISA
BDC-2.5 T cell hybridomas (2x104 cell per well) were stimulated with the recombinant
proteins for 48 hrs in complete RPMI media. IFN-γ secretion was detected by sandwich
ELISA following the manufacture’s instructions (Ready-set-Go Mouse-IFN-γ Femto-HS,
eBioscience).
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Nested RT-PCR was carried out as published [24]. Briefly, splenocytes of mice treated
orally with CTB-2.5mi were stained by tetramers and anti-CD4-APC, anti-CD8-PerCP, anti-
CD19-PerCP as well as PI. Twenty CD4+2.5mi+Foxp3− or CD4+2.5mi+Foxp3+ T cells were
sorted using a FACSaria II sorter (Becton Dickinson) directly into 50 μl of cDNA reaction
mixture. Generated cDNA (2 μl per PCR reaction) was used for nested PCR as published
[24].
ELISPOT Assays
ELISPOT assays were carried out using antibody pairs for mouse IFN-γ and IL-4
(BioLegend) as indicated by the manufacture. Total splenocytes from orally treated
(CTB-2.5mi or PBS) female NOD mice were isolated 4 days after the last immunization as
described above and 5x105 cells/well were plated in RPMI+10%FBS in the absence or
presence of 10 or 100 ng/ml of CTB-2.5mi or CTB only to establish the response against the
2.5 mi peptide versus CTB on ELISPOT plates (Millipore). After 48 hrs of incubation at
37°C, ELISPOT assays were processed as indicated by the manufacturer using peroxidase-
labeled streptavidin for secondary Ab detection and 3-amino-9-ethylcarbazole for color
reaction (AEC, Sigma-Aldrich, Mo, USA). Spots were quantified using an automated
ELISPOT reader system (C.T.L. Cellular Technology Ltd.).
Treatment of mice
Oral treatment was typically initiated at 5 to 8 weeks of age. Mice were administered 200 μg
of CTB-2.5mi or CTB per dose intragastrically every 3 to 4 days, 5 or 10 doses total. In
some cases, 4 days after the last dose, mice were immunized with 50 μg of CTB-2.5mi
intraperitoneally. T cell responses were typically analyzed 4 days later.
All experiments were performed in accordance with the Animal Care and Veterinary
Services and approved by the Ethics Committee of Animal Experimentation of the
Barcelona Science Park.
Flow cytometry analysis
Antigen-specific T cell analysis was carried out as previously described [15, 17]. Briefly,
single-cell suspensions were blocked with avidin (Sigma) in FACS buffer (PBS containing
2% FCS and 0.04% NaN3) and stained with PE-labeled MHC/peptide tetramers on ice.
Depending on the combination of surface marker analysis, FITC-, APC- as well as Alexa
Fluor-700–anti-CD4, anti-CD8-PE-Cy5, anti-CD19-PE-Cy5, anti-CD44-Pacific Blue, and
anti-CD62L-APC-Cy7 were used (BioLegend, CA, USA). Dead cells were excluded by
addition of propidium iodide. Flow cytometry was performed using a FACScan, a
FACScalibur or a FACSAria II instrument (Becton Dickinson Immunocytometry Systems,
Mountain View, California, USA), and data were analyzed using the FlowJo software (Tree
Star Inc, Ashland OR, USA).
Statistical analysis
Bar diagrams were analyzed using the GraphPad Prism software and the Bonferroni test for
selected pairs of columns or unpaired t test. Cumulative incidence of diabetes was
determined by Kaplan-Meier estimates using the GraphPad Prism software version 5.0, and
curves analyzed by log-rank test for statistical differences.
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Generation of CTB-2.5mi fusion protein
Previous studies have shown that oral administration of CTB fused or conjugated with
insulin led to T1D protection in the NOD mouse [9, 10]. We investigated how oral
administration of the strong 2.5mi peptide agonist [15, 16], fused to CTB affected 2.5mi+ T
cells. To this end, we generated a construct that encoded CTB, followed by the 2.5mi or the
GAD286–300 peptide embedded in-between 2 linker peptides and a C-terminal histidine tag
(Fig. 1A). Expression of CTB fusion proteins in E. coli and subsequent purification led to
homogenous protein complexes as revealed by a single peak during size exclusion
chromatography (Fig. 1B, only CTB-2.5mi is shown). SDS-PAGE analysis under denaturing
and non-denaturing conditions indicated that the protein contained a functional CTB moiety
as indicated by the formation of pentamers that were disrupted in presence of SDS and β-
mercaptoethanol (Fig. 1C). Proper refolding of CTB was further indicated by binding to
immobilized D-galactose ([25]; not shown).
CTB-2.5mi stimulates Ag-specific T cell in vitro and in vivo
We next investigated the capacity of CTB-2.5mi to be processed and presented to BDC-2.5
responder T cells in vitro. The BDC-2.5 hybridoma and total NOD-mouse derived
splenocytes as source of antigen presenting cells were incubated in presence of increasing
amounts of CTB-2.5mi or a synthetic version of the 2.5mi peptide and IFN-γ production was
measured after 48 hrs of cultivation. The potency of CTB-2.5mi to stimulate IFN-γ
production was more than 80-fold compared to the synthetic peptide (Fig. 1D). Therefore,
CTB-2.5mi was properly processed and suitable to strongly stimulate Ag-specific T cells.
We next examined how CTB-2.5mi stimulated 2.5mi+ T cells in vivo in comparison to the
synthetic peptide. In order to simultaneously assess the generation of Ag-specific Foxp3+ T
cells, we used NODxB6.Foxp3EGFP F1 reporter mice as we previously showed that these
mice generate 2.5mi+ T cells as well as Foxp3+ Treg with the same specificity
(2.5mi+Foxp3+ CD4 T cells; [17]). Females were injected with equimolar amounts of either
CTB-2.5mi or the synthetic 2.5mi peptide i.p. in the absence of adjuvant and proliferation of
Ag-specific T cells was analyzed at day 4 p.i. by tetramer staining. A 10-fold stronger T cell
proliferation was detected in the spleen when the CTB fusion protein was used compared to
the synthetic peptide in both effector T cells (2.5mi+Foxp3−) and iTreg (2.5mi+Foxp3+)
(Fig. 2 A and B; see supplemental Table S1 for absolute cell numbers). Taken together, our
studies show that fusion of the 2.5mi peptide to CTB favors 2.5mi+ T cells expansion as
well as their feeding into the iTreg pool when administered i.p.
CTB-2.5mi induces Ag-specific T cell tolerance in NODxB6.Foxp3EGFP F1, but not in NOD
mice
It was previously shown that oral tolerance is generated via Th2 cells, iTreg and T cell
anergy [26–29]. To investigate whether CTB-2.5mi induced Ag-specific tolerance, we first
treated NOD mice 5 times by i.g. delivery of the fusion protein. Four days after the last dose,
we either tested the presence of 2.5mi+ T cells, or injected CTB-2.5mi intraperitoneally (i.p.)
and then analyzed for 2.5mi+ T cells 4 days later. As controls, we analyzed either age-
matched naive littermates, or littermates that had received CTB-2.5mi i.p. without prior i.g.
treatment. The frequencies of 2.5mi+ T cells detected in naive versus i.g. treated mice were
essentially undistinguishable in the spleen and mesenteric LN (MLN) (Fig. 3A, B and C; see
supplemental Table S2 for absolute cell numbers). I.p. administration of CTB-2.5mi led to a
strong proliferation of 2.5mi+ T cells, regardless of i.g. treatment. We corroborated these
findings in a second NOD colony (NOD/LtDvs) in a different laboratory (D. Serreze,
Jackson) (Fig. 4, J and K). Therefore, CTB-2.5mi was unable to induce oral tolerance in
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NOD mice as defined by the inability to prevent Ag-specific T cell expansion after i.p.
challenge with Ag.
Despite possessing 2.5mi+ T cells [17], NODxB6 F1 mice do not develop T1D and are
tolerant to self. In order to analyze whether the failure of CTB-2.5mi to induce oral tolerance
was intrinsic to the protein or to the NOD genetic background, we repeated the same
experiments using NODxB6.Foxp3EGFP F1 reporter mice. This allowed simultaneously
monitoring 2.5mi+ T effector cells and Ag-specific iTreg. Compared to PBS treated controls,
expansion of 2.5mi+ T cells was significantly suppressed in the spleen and to a less extent
the MLN of CTB-2.5mi orally treated NODxB6.Foxp3EGFP F1 mice that became evident
when both groups were boosted i.p. with CTB-2.5mi (Fig. 4A, D and G). Oral treatment led
to a significant increase of 2.5mi+Foxp3+ T cells among total CD4 T cells in the MLN but
not in the spleen (Fig. 4B and E). Following i.p. boost challenge with the protein after i.g.
treatment, the proportion of Foxp3+ T cells within the 2.5mi+ T cell subpopulation increased
significantly in both tissues (Fig. 4C and F). Therefore, contrarily to NOD mice, T1D
resistant NODxB6.Foxp3EGFP F1 controls were able to mount oral tolerance to CTB-2.5mi.
While Foxp3+ Ag-specific Treg were generated, due to the rather small amounts, however,
their role is questionable. These results suggest that NOD mice have a recessive genetic
resistance to induce oral tolerance to CTB-2.5mi that can be overcome by a single outcross
into the B6 background. The differential response to CTB-2.5mi was restricted to the oral
route since we did not detect any difference in NOD versus NODxB6.Foxp3EGFP F1
reporter mice in either the percentage or duration of 2.5mi+ Tconv and Treg cell expansion
after i.p. challenge only (M.P. and T.S., manuscript in preparation). We carried out a further
control study to test if the ability to establish tolerance to orally administered CTB-2.5mi in
NODxB6.Foxp3EGFP F1, but not NOD mice was a phenomenon restricted to a comparison
of these particular two strains. Thus, we compared the ability to establish tolerance to orally
administered CTB-2.5mi in NOD mice to the closely related H2g7 matched, but T1D
resistant NOR control strain [19]. Following previous oral treatment with CTB-2.5mi,
subsequent i.p. primed CD4 T cell responses to this antigen were significantly less in
spleens and MLNs of NOR than NOD mice (Fig. 4H and I). It should be pointed out that
NOR background mice carrying the Foxp3EGFP reporter are currently not available. For this
reason it was not possible to determine if the greater ability to establish tolerance to orally
administered CTB-2.5mi in NOR than NOD mice was due to variable conversion of CD4 T
cells recognizing this antigen into the Treg compartment. To analyze whether these findings
were limited to the 2.5mi agonist peptide, we repeated the same set of experiments with
GAD286–300 fused to CTB in NOD versus NOR mice and analyzed Ag-specific T cells by
tetramers complexed to this peptide (Supplemental Fig. S1 A and B). Again, NOD but not
NOR mice were incapable to mount oral tolerance to CTB-GAD286–300. These collective
results indicate the susceptibility of NOD mice to development of autoimmune T1D is
associated with the strain characteristic of an impaired ability to establish CD4 T cell
tolerance to an orally administered antigen.
Restoring the NOD background in Foxp3EGFP reporter mice should eliminate the ability to
establish oral tolerance. We thus further backcrossed the Foxp3EGFP reporter from the F1
hybrids for 6 generations to the NOD strain to generate NOD.Foxp3EGFP animals. While
oral treatment led to a weak but significant reduction of 2.5mi+ T cells in MLN, the mice
were unable to suppress T cell expansion in the spleen as predicted (Fig. 5A and D).
Interestingly, compared to controls NOD.Foxp3EGFP females produced significantly more
2.5mi+Foxp3+ T cells in the spleen and MLN (Fig. 5B, C, E and F). Therefore, the inability
of NOD mice to be rendered tolerant to orally administered CTB-2.5mi is not due to a
failure of this antigen to induce an expansion of Foxp3+ Tregs. Instead, the current findings
would be consistent with previous reports that diabetogenic effector T cells in NOD mice
become refractive to the suppressive effects of Tregs [30].
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Oral administration of CTB-2.5mi results in a strong induction of IFN-γ and IL-4 in NOD
mice
Since CTB-2.5mi did not induce Ag-specific oral tolerance in the NOD background, we next
investigated whether this was associated with a particular Th1 to Th2 cytokine production
balance. NOD.Foxp3EGFP and NODxB6 F1 mice received 5 doses of CTB-2.5mi or PBS
i.g., and sorted 2.5mi+ Teff cells were analyzed for cytokine expression by RT-PCR. In F1
animals neither Th1 (IFN-γ) or Th2 (IL-4) cytokine expression by 2.5mi+ T cells was
detected. However, these cells expressed both cytokines in NOD.Foxp3EGFP mice (Fig 6A).
ELISPOT assays carried out in parallel revealed that in both strains, oral treatment with
CTB-2.5mi significantly increased IFN-γ as well as IL-4 cytokine production. However,
NOD mice generated significantly more cells producing either of these cytokines compared
to NODxB6 F1 mice (Fig. 6, B and C and supplemental Fig. S2). The in vitro response was
specific for the 2.5mi peptide as control cultures containing CTB only as a source of Ag
generated negligible amounts of IFN-γ or IL-4 (Fig. 6, B and C). Therefore, a failure to
induce a Th1 to Th2 cytokine production shift could not explain the impaired tolerogenic
effect of oral CTB-2.5mi administration in NOD mice as Th2 cells were amply generated
but could not prevent the generation of IFN-γ producing Th1 cells.
Oral antigen administration results in a greater proportion of naive 2.5mi+ T cells in
NODxB6 F1 than NOD mice
Based on their greater level of cytokine production we tested if 2.5mi+ T cells are activated
more readily in response to orally administered antigen in NOD than NODxB6 F1 mice. To
determine the activation status of 2.5mi+ T cells in NOD.Foxp3EGFP and
NODxB6.Foxp3EGFP F1 mice, animals received either 5 doses of CTB-2.5mi i.g. or mock-
treatment with PBS, and splenic 2.5mi+ T cells were analyzed for simultaneous CD44 and
CD62L expression. In mock-treated NODxB6.Foxp3EGFP F1 mice, the majority of
2.5mi+Foxp3− T cells had a naive phenotype (CD44−CD62L+) and oral treatment did not
significantly affect the composition of the naive, central memory (CD44+CD62L+) or
effector memory (CD44+CD62L−) populations (Fig. 7A, see supplemental Table S3 for
absolute cell numbers). In contrast, oral treatment of NOD.Foxp3EGFP animals had a drastic
effect on 2.5mi+Foxp3− T cells. CTB-2.5mi treatment induced strong activation and a
significant shift towards the effector memory T cell pool (Fig. 7B, see supplemental Table
S3 for absolute cell numbers). The same effect was observed in pancreatic lymph nodes (not
shown). Therefore, rather than inducing tolerance, oral treatment with CTB-2.5mi induced T
cell activation in the diabetes-prone NOD background but not in disease-resistant
NODxB6.Foxp3EGFP F1 mice.
Oral administration of CTB-2.5mi does not prevent T1D
It was possible that an incompatibility of the 2.5mi strong agonist peptide together with CTB
as carrier molecule was responsible for the oral administration of this agent inducing T cell
activation rather than tolerance induction in NOD mice. To test this hypothesis, 5-week-old
female NOD mice were treated every 3–4 days by i.g. delivery with a total of 5 doses of
CTB-2.5mi, CTB only, or PBS, and diabetes onset was monitored. Disease was neither
delayed nor reduced by CTB-2.5mi. If anything, treatment slightly accelerated disease
(Supplemental Fig. S3). Incrementing the dose and time of treatment to a total of 10 i.g.
injections did not change this outcome. The failure of CTB-2.5mi to induce systemic
tolerance was unlikely due to the 2.5mi epitope itself since this peptide could prevent
disease when administered in form of a DNA vaccine [17]. Neither was it likely due to the
route of administration since CTB-2.5mi, when administered i.p., likewise was unable to
prevent disease (M.P. and T.S., unpublished). Collectively, the results point towards an
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incompatibility of CTB in combination with a strong peptide agonist such as 2.5mi to induce
tolerogenic responses in the NOD background.
DISCUSSION
The success of immunological tolerance induction in the NOD mouse depends on many
factors such as the route of Ag applications, the nature of the Ag itself as well as the
adjuvant. To study oral tolerance in the NOD mouse, we reduced the antigenic complexity
of an oral vaccine to 2 peptides, the 2.5 mimotope and a GAD derived peptide, since we
could trace the outcome on the corresponding CD4 T cell populations using MHC tetramers.
The 2.5mi epitope can induce T1D protective tolerance in the NOD mouse when given as
targeted DNA vaccine [17] or as soluble Ag7/peptide dimer [31]. Therefore, the 2.5mi
epitope is a good candidate to compare the fate of Ag-specific, autoreactive T cells
depending on the routes and adjuvants used for application. In this report, we focused on
CTB due to its reported adjuvant effect [32, 33] and its capacity to suppress diabetes with
antigens such as insulin or GAD-derived peptides [6, 8]. However, none of these studies
have analyzed in detail the fate of Ag-specific T cells by MHC tetramers. I.p. delivery of
CTB strongly enhanced the expansion of 2.5mi+ T cells in comparison to administration of
the synthetic peptide. However, oral treatment of NOD mice with CTB-2.5mi neither
prevented nor delayed disease but rather slightly accelerated it. Several mechanisms have
been reported to be responsible for oral tolerance induction, including the generation of
Foxp3+ Treg [34, 35], Th3 cells [36], a shift from a Th1 to a Th2 cytokine production profile
[4], and T cell anergy [37, 38]. In murine diabetes models, the generation of Treg as well as
of Th2 protective T cells have been reported, but due to lacking tools neither T cell anergy
nor T cell deletion have been experimentally approached. Treatment of NOD mice with
CTB-2.5mi did not delete 2.5mi+ T cells but induced Ag-specific Foxp3+ Treg, Th2, and
also Th1 cells. Neither Treg not Th2 cells were sufficient to protect from disease, possibly
since 2.5mi+ T cell with a Th2 profile might be as diabetogenic as Th1 cells as previously
demonstrated [39].
Since NODxB6.Foxp3EGFP F1 and NOR mice were fully capable of suppressing the
expansion of 2.5mi+ T cells when treated orally, sufficient CTB-2.5mi protein survives in
the intestine to be presented by APCs to these T cells. The problem therefore did not lie in
the inappropriate degradation of CTB-2.5mi. When the NOD background was reestablished
by further backcrossing the Foxp3EGFP reporter into NOD, the ability to generate oral
tolerance was lost in the spleen and only a weak effect was detected in the MLN. The
difference in the MLN between our NOD and NOD.Foxp3EGFP mice might be due to minor
animal-to-animal variations or to the fact that NOD.Foxp3EGFP mice still carried some parts
of the B6 specific background. Together, this clearly demonstrates a recessive constraint in
oral tolerance induction of the NOD strain when using CTB in combination with a strong
agonist peptide. The inability of the NOD strain to mount oral tolerance was not limited to
the 2.5 mimotope which might follow different rules considering that it is a strong agonist
peptide but held also true for a natural epitope, in this case GAD286–300.
Levels of 2.5mi responsive Th1 and Th2 cells increased significantly in both NOD and
NODxB6.Foxp3EGFP F1 mice orally treated with this antigen. However, there was a
remarkable difference: the numbers of IFN-γ as well as IL-4 producing cells after oral
immunization were significantly higher in NOD versus NODxB6 F1 mice. These
observations corroborate a previous report showing that NOD-derived CD4 T cells are more
prone than those from B6.H2g7 mice to produce IFN-γ [40]. We show here that this is not
limited to IFN-γ but also holds true for IL-4.
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A striking difference between the NOD and the NODxB6 F1 background was found in naive
versus orally treated mice in the conventional (Foxp3−) 2.5mi+ T cell population. Following
oral CTB-2.5mi treatment, CD4 T cells recognizing this antigen remained mostly naive in
NODxB6 F1 mice, but were diverted primarily into the effector memory pool in NOD mice.
These data are in accordance with a recent report showing that when generated in B6.H2g7
mice, BDC-2.5 TCR transgenic T cells proliferate less in vitro and in vivo upon stimulation
in comparison to the same clonotype originating in the NOD strain [30]. The difference was
traced to strain dependent variations in BDC-2.5 effector rather than to Treg activity [30].
Our data expand this observation to polyclonal 2.5mi+ T cells and show that this is a
recessive trait of the NOD background.
In light of these results, how may the reported success of other groups to induce T1D
protection using CTB coupled autoantigens in the NOD mouse be explained? Differences in
the treatment protocol are an unlikely explanation since in the case of CTB conjugated to
insulin, even a single i.g. dose has been reported to protect from the disease [9]. The strong
adjuvant effect of CTB together with a strong agonist peptide such as 2.5mi might be the
underlying problem why diabetes was not prevented. We did not carry out long-term
diabetes prevention trials with the GAD peptide. However, the inability of the NOD strain to
mount oral tolerance against CTB-coupled peptides was not restricted to the BDC2.5
mimotope, but also extended to the GAD peptide. A previous report has shown that
GAD531–545 when fused as trimer to CTB can induce oral tolerance [6]. An intensive oral
treatment (4 times weekly, from 5 – 35 weeks of age) was necessary to achieve a 60%
reduction of diabetes in NOD mice. It has been previously reported that GAD524–538 induces
a regulatory T cell population upon immunization [41]. It may depend on the constellation
of the preexisting T cell population (effector versus regulatory) which of them will
preferentially expand and tip the balance from tolerance to effector function. When we
treated NOD mice with three doses of a lysosome-targeted DNA vaccine, the same
mimotope could induce protection and delay of the disease [17]. Therefore, the combination
of the mimotope together with CTB is less efficient than when applied in a DNA vaccine
formulation where the peptide is targeted intracellularly to lysosomes. Recent experiments
in our laboratory have demonstrated that CTB-2.5mi is equally unable to prevent disease
when administered i.p. (not shown). Over the last 15 years, however, the progress on
diabetes suppression with CTB based oral fusion vaccines has been modest. Since early
reports where 50% diabetes suppression was demonstrated [9, 11], to our knowledge the
strongest suppression to date (60%) has been achieved using GAD peptide 531–545 fused as
trimer to CTB as mentioned above [6]. These data indicate that solid diabetes suppression
using CTB as fusion partner has remained difficult to obtain.
In conclusion, the genetic background is essential when trying to elaborate oral antigen
treatment protocols since autoimmune-prone strains behave very differently compared to
well-established standard models. The NOD strain has a clear impairment to mount oral
tolerance, at least with the two peptides analyzed when fused to CTB, in comparison to
disease-resistant strains. It will be important to consider these observations when engaging
into the much more complex world of human trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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References
1. Sanchez J, Holmgren J. Cholera toxin structure, gene regulation and pathophysiological and
immunological aspects. Cell Mol Life Sci. 2008; 65:1347–1360. [PubMed: 18278577]
2. Mathis D, Vence L, Benoist C. Beta-Cell death during progression to diabetes. Nature. 2001;
414:792–798. [PubMed: 11742411]
3. Shoda LKM, Young DL, Ramanujan S, Whiting CC, Atkinson MA, Bluestone JA, Eisenbarth GS,
et al. A Comprehensive Review of Interventions in the NOD Mouse and Implications for
Translation. Immunity. 2005; 23 :115–126. [PubMed: 16111631]
4. Ploix C, Bergerot I, Durand A, Czerkinsky C, Holmgren J, Thivolet C. Oral administration of
cholera toxin B-insulin conjugates protects NOD mice from autoimmune diabetes by inducing
CD4+ regulatory T-cells. Diabetes. 1999; 48:2150–2156. [PubMed: 10535448]
5. Aspord C, Czerkinsky C, Durand A, Stefanutti A, Thivolet C. α4 Integrins and L-selectin
Differently Orchestrate T-cell Activity During Diabetes Prevention Following Oral Administration
of CTB-insulin. J Autoimmunity. 2002; 19:223–232. [PubMed: 12473243]
6. Gong Z, Pan L, Le Y, Liu Q, Zhou M, Xing W, Zhuo R, et al. Glutamic acid decarboxylase epitope
protects against autoimmune diabetes through activation of Th2 immune response and induction of
possible regulatory mechanism. Vaccine. 2010; 28:4052–4058. [PubMed: 20406664]
7. Denes B, Krausova V, Fodor N, Timiryasova T, Henderson D, Hough J, Yu J, et al. Protection of
NOD Mice From Type 1 Diabetes After Oral Inoculation with Vaccinia Viruses Expressing
Adjuvanted Islet Autoantigens. J Immunother. 2005; 28:438–448. [PubMed: 16113600]
8. Bregenholt S, Wang M, Wolfe T, Hughes A, Bærentzen L, Dyrberg T, Von Herrath MG, et al. The
Cholera Toxin B Subunit is a Mucosal Adjuvant for Oral Tolerance Induction in Type 1 Diabetes.
Scand J Immunol. 2003; 57:432–438. [PubMed: 12753499]
9. Bergerot I, Ploix C, Petersen J, Moulin V, Rask C, Fabien N, Lindblad M, et al. A cholera toxoid-
insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci.
1997; 94:4610–4614. [PubMed: 9114038]
10. Gong Z, Jin Y, Zhang Y. Suppression of diabetes in non-obese diabetic (NOD) mice by oral
administration of a cholera toxin B subunit-insulin B chain fusion protein vaccine produced in
silkworm. Vaccine. 2007; 25:1444–1451. [PubMed: 17113687]
11. Arakawa T, Yu J, Chong DKX, Hough J, Engen PC, Langridge WHR. A plant-based cholera toxin
B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat
Biotech. 1998; 16:934–938.
Presa et al. Page 10













12. Achenbach P, Barker J, Bonifacio E. Modulating the natural history of type 1 diabetes in children
at high genetic risk by mucosal insulin immunization. Curr Diabetes Reports. 2008; 8:87–93.
13. Sánchez J, Holmgren J. Cholera toxin - a foe & a friend. Ind J Med Res. 2011; 133:153–163.
14. Haskins K, McDuffie M. Acceleration of diabetes in young NOD mice with a CD4+ islet-specific
T cell clone. Science. 1990; 249:1433–1436. [PubMed: 2205920]
15. Stratmann T, Martin-Orozco N, Mallet-Designe V, Poirot L, McGavern D, Losyev G, Dobbs CM,
et al. Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J
Clin Invest. 2003; 112:902–914. [PubMed: 12975475]
16. Yoshida K, Martin T, Yamamoto K, Dobbs C, Munz C, Kamikawaji N, Nakano N, et al. Evidence
for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived,
islet-specific, diabetogenic T cell clones. Int Immunol. 2002; 14:1439–1447. [PubMed: 12456592]
17. Rivas EI, Driver JP, Garabatos N, Presa M, Mora C, Rodriguez F, Serreze DV, et al. Targeting of a
T Cell Agonist Peptide to Lysosomes by DNA Vaccination Induces Tolerance in the Nonobese
Diabetic Mouse. J Immunol. 2011; 186:4078–4087. [PubMed: 21346228]
18. Haribhai D, Lin W, Relland LM, Truong N, Williams CB, Chatila TA. Regulatory T Cells
Dynamically Control the Primary Immune Response to Foreign Antigen. J Immunol. 2007;
178:2961–2972. [PubMed: 17312141]
19. Prochazka M, Serreze DV, Frankel WN, Leiter EH. NOR/Lt Mice: MHC-Matched Diabetes-
Resistant Control Strain for NOD Mice. Diabetes. 1992; 41:98–106. [PubMed: 1727742]
20. Chao C-C, McDevitt HO. Identification of immunogenic epitopes of GAD 65 presented by Ag7 in
non-obese diabetic mice. Immunogenetics. 1997; 46:29–34. [PubMed: 9148785]
21. Arêas AP, Oliveira ML, Ramos CR, Sbrogio-Almeida ME, Raw I, Ho PL. Synthesis of cholera
toxin B subunit gene: cloning and expression of a functional 6XHis-tagged protein in Escherichia
coli. Prot Expr Purif. 2002; 25:481–487.
22. Stratmann T, Apostolopoulos V, Mallet-Designe V, Corper AL, Scott CA, Wilson IA, Kang AS, et
al. The I-Ag7 MHC Class II Molecule Linked to Murine Diabetes Is a Promiscuous Peptide
Binder. J Immunol. 2000; 165:3214–3225. [PubMed: 10975837]
23. Corper AL, Stratmann T, Apostolopoulos V, Scott CA, Garcia KC, Kang AS, Wilson IA, et al. A
Structural Framework for Deciphering the Link Between I-Ag7 and Autoimmune Diabetes.
Science. 2000; 288:505–511. [PubMed: 10775108]
24. Panus JF, McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific T Helper Cell
Function: Differential Cytokine Expression in Primary and Memory Responses. J Exp Med. 2000;
192:1301–1316. [PubMed: 11067879]
25. Tinker JK, Erbe JL, Holmes RK. Characterization of fluorescent chimeras of cholera toxin and
Escherichia coli heat-labile enterotoxins produced by use of the twin arginine translocation
system. Infect Immun. 2005; 73:3627–3635. [PubMed: 15908392]
26. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral
tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the
release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci.
1992; 89:421–425. [PubMed: 1370356]
27. Melamed D, Friedman A. Direct evidence for anergy in T lymphocytes tolerized by oral
administration of ovalbumin. Eur J Immunol. 1993; 23:935–942. [PubMed: 8458379]
28. Hadis U, Wahl B, Schulz O, Hardtke-Wolenski M, Schippers A, Wagner N, Muller W, et al.
Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina
propria. Immunity. 2011; 34:237–246. [PubMed: 21333554]
29. Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille JJ, Curotto de Lafaille MA. Oral tolerance
in the absence of naturally occurring Tregs. J Clin Invest. 2005; 115:1923–1933. [PubMed:
15937545]
30. D’Alise AM, Auyeung V, Feuerer M, Nishio J, Fontenot J, Benoist C, Mathis D. The defect in T-
cell regulation in NOD mice is an effect on the T-cell effectors. Proc Natl Acad Sci. 2008;
105:19857–19862. [PubMed: 19073938]
31. Masteller EL, Warner MR, Ferlin W, Judkowski V, Wilson D, Glaichenhaus N, Bluestone JA.
Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in
Autoimmune Diabetes. J Immunol. 2003; 171:5587–5595. [PubMed: 14607967]
Presa et al. Page 11













32. Grdic D, Ekman L, Schön K, Lindgren K, Mattsson J, Magnusson K-E, Ricciardi-Castagnoli P, et
al. Splenic Marginal Zone Dendritic Cells Mediate the Cholera Toxin Adjuvant Effect:
Dependence on the ADP-Ribosyltransferase Activity of the Holotoxin. J Immunol. 2005;
175:5192–5202. [PubMed: 16210624]
33. Tarkowski A, Sun J-B, Holmdahl R, Holmgren J, Czerkinsky C. Treatment of experimental
autoimmune arthritis by nasal administration of a type II collagen–cholera toxoid conjugate
vaccine. Arthritis Rheum. 1999; 42:1628–1634. [PubMed: 10446861]
34. Broere F, Wieten L, Klein Koerkamp EI, van Roon JAG, Guichelaar T, Lafeber FPJG, van Eden
W. Oral or Nasal Antigen Induces Regulatory T Cells That Suppress Arthritis and Proliferation of
Arthritogenic T Cells in Joint Draining Lymph Nodes. J Immunol. 2008; 181:899–906. [PubMed:
18606641]
35. Fukaya T, Takagi H, Sato Y, Sato K, Eizumi K, Taya H, Shin T, et al. Crucial roles of B7-H1 and
B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific
CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. Blood. 116:2266–2276.
[PubMed: 20574047]
36. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral
tolerance: suppression of autoimmune encephalomyelitis. Science. 1994; 265:1237–1240.
[PubMed: 7520605]
37. Ise W, Nakamura K, Shimizu N, Goto H, Fujimoto K, Kaminogawa S, Hachimura S. Orally
Tolerized T Cells Can Form Conjugates with APCs but Are Defective in Immunological Synapse
Formation. J Immunol. 2005; 175:829–838. [PubMed: 16002680]
38. Mirenda V, Millington O, Lechler RI, Scott D, Hernandez-Fuentes MP, Read J, Tan PH, et al.
Tolerant T cells display impaired trafficking ability. Eur J Immunol. 2005; 35:2146–2156.
[PubMed: 15948215]
39. Poulin M, Haskins K. Induction of Diabetes in Nonobese Diabetic Mice by Th2 T Cell Clones
from a TCR Transgenic Mouse. J Immunol. 2000; 164:3072–3078. [PubMed: 10706696]
40. Koarada S, Wu Y, Ridgway WM. Increased Entry into the IFN-γ Effector Pathway by CD4+ T
Cells Selected by I-Ag7 on a Nonobese Diabetic Versus C57BL/6 Genetic Background. J
Immunol. 2001; 167:1693–1702. [PubMed: 11466393]
41. Quinn A, McInerney B, Reich EP, Kim O, Jensen KP, Sercarz EE. Regulatory and Effector CD4 T
Cells in Nonobese Diabetic Mice Recognize Overlapping Determinants on Glutamic Acid
Decarboxylase and Use Distinct Vβ Genes. J Immunol. 2001; 166:2982–2991. [PubMed:
11207247]
Presa et al. Page 12













FIGURE 1. Generation of the CTB-2.5mi fusion protein and in vitro stimulation of BDC-2.5
(A) Schematic representation of the CTB-2.5mi construct. The 2.5mi peptide is fused C-
terminally to CTB and is embeded by 2 linker sequences, followed by a hexahistidine tag
and a vector-encoded 2 aa tail (GS). The aa sequences of the linkers and the peptide are
indicated.
(B) Elution profile of size exclusion chromatography of CTB-2.5mi.
(C) SDS-PAGE and Western blot analysis of purified CTB-2.5mi. The monomeric (15 KD)
and pentameric (75KD) forms are shown by SDS-PAGE analysis under denaturing (reduced
with β-mercaptoethanol and heated) and native (without β-mercaptoethanol and not heated)
conditions, respectively, and the recombinant protein identity revealed by Western blot
using an anti-hexahistidine tag antibody.
(D) Comparison of T cell activation by CTB-2.5mi versus the synthetic 2.5mi peptide (s.p.
2.5mi). The BDC-2.5mi T cell hybridoma was incubated with NOD-derived splenocytes as
APCs at the indicated molar concentrations of the respective protein or peptide and T cell
activation quantified by IFN-γ detection through ELISA. Error bars represent SEM of 2
independent experiments; each point was collected in triplicate per experiment.
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FIGURE 2. In vivo expansion of 2.5mi+ T Cells by CTB-2.5mi
NODxB6.Foxp3EGFP F1 females (n=3) were immunized i.p. with 6.5 nmol of synthetic
peptide 2.5m or CTB-2.5mi. Four days later, expansion of antigen-specific CD4 T cells was
analyzed by staining with Ag7/2.5mi or Ag7/GPI282–292 control tetramers and analyzed by
FACS.
(A) Representative FACS profiles showing the percentage of splenic 2.5mi+ effector T cells
and 2.5mi+Foxp3+ Treg. T cells were gated on B220−, CD8−, PI− and CD4+.
(B) Bar diagram of the same experiment showing the mean ± SEM of the percentage 2.5mi+
effector T cells (top) and 2.5mi+Foxp3+ Treg (bottom; **p<0.01, ***p<0.0001). The
diagram was generated from 2 independent experiments, using 3 mice per experiment and
type of treatment.
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FIGURE 3. 2.5mi+ T cells are not tolerized by oral treatment with CTB-2.5mi in NOD mice
Five-to-6-week-old NOD females were treated with 5 doses of 200 μg CTB-2.5mi every 3 to
4 days i.g. (ORAL) and analyzed 4 days after the last dose for Ag-specific 2.5mi+ T cell
expansion in the spleen (A) and in mesenteric lymph nodes (B; MLN) as explained in the
legend for Fig. 2 by tetramer staining and FACS analysis. Unmanipulated littermates served
as baseline control (CTRL-Naive). Alternatively, 4 days after the last oral dose, mice
received a boost immunization i.p. with 50 μg of CTB-2.5mi, were rested for an additional 4
days, and next analyzed as above (ORAL-IP). As controls, littermates were immunized i.p.
without receiving the protein i.g. (CTRL-IP). Mean values ± SEM of 2 independent
experiments including 6 animals per group and treatment are shown. Values represent
percentages of 2.5mi+CD4+ T cells within total CD4+ T cells, gated on B220−, CD8−, PI−
and CD4+ cells.
(C) Representative FACS profiles of splenocytes of NOD mice treated and analyzed as
explained above.
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FIGURE 4. Tolerization of 2.5mi+ T cells by oral treatment with CTB-2.5mi in
NODxB6.Foxp3EGFP F1 and NOR mice
Five-to-6-week-old NOD, NODxB6.Foxp3EGFP F1, or NOR females were treated with 5
doses of 200 μg CTB-2.5mi every 3 to 4 days i.g. (ORAL) or PBS at the same times (CTRL-
Naive ) and analyzed 4 days after the last dose for Ag-specific 2.5mi+ T cell expansion in
the spleen as explained in the legend for Fig. 2 by tetramer staining and FACS analysis.
Alternatively, 4 days after the last oral dose, mice received a boost immunization i.p. with
50 μg of CTB-2.5mi, were rested for an additional 4 days, and next analyzed as above
(ORAL-IP versus CTRL-IP). Mean values ± SEM of 2 independent experiments including 6
animals per group and treatment are shown (***p <0.0001; *p <0.05).
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(A, D) Bar diagrams represent percentages of 2.5mi+CD4+ T cells within total CD4+ T cells
in the spleens or MLNs of variously treated NODxB6.Foxp3EGFP F1 mice.
(B, E) Bar diagrams represent percentages of 2.5mi+Foxp3+ T cells among total CD4+ T
cells within spleens or MLNs of variously treated NODxB6.Foxp3EGFP F1 mice.
(C, F) Bar diagrams represent percentages of 2.5mi+Foxp3+ T cells among total 2.5mi+ T
cells within spleens or MLNs of variously treated NODxB6.Foxp3EGFP F1 mice.
(G) Representative FACS data from the same experimental analyses of
NODxB6.Foxp3EGFP F1 mice. Analysis of the spleen is shown. Top: Ag7/2.5mi tetramer+ T
cells are analyzed within total CD4+ T cells. Middle: Ag7/2.5mi tetramer+ Foxp3+ T cells
are analyzed within total CD4+ T cells. Bottom: Foxp3+ T cells are analyzed within
Ag7/2.5mi tetramer+ T cells. Left: Mice received CTB-2.5mi i.p. only. Right: Mice were
treated first with CTB-2.5mi i.g. and next received the protein i.p.
(H, I, J and K) Comparison of 2.5mi+CD4+ T cells within total CD4+ T cells in the spleens
or MLNs of NOD and NOR mice (colonies D. Serreze, Jackson Laboratories) within each
designated treatment group. H and J, spleen, I and K, MLN.
For the analysis, cells were gated on B220−, CD8−, PI− and CD4+ cells.
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FIGURE 5. Failure to achieve tolerance of 2.5mi+ T cells by oral treatment with CTB-2.5mi in
NOD.Foxp3EGFP mice
Five-to-6-week-old NOD.Foxp3EGFP females (Foxp3EGFP reporter backcrossed for 6
generations into the NOD strain) were treated with 5 doses of 200 μg CTB-2.5mi every 3 to
4 days i.g. and analyzed 4 days after the last dose for Ag-specific 2.5mi+ T cell expansion in
the spleen as explained in the legend for Fig. 2 by tetramer staining and FACS analysis
(ORAL and CTRL-Naive). Alternatively, 4 days after the last oral dose, mice received a
boost immunization i.p. with 50 μg of CTB-2.5mi, were rested for an additional 4 days, and
next analyzed as above (ORAL-IP and CTRL-IP). Mean values ± SEM of 2 independent
experiments including 6 animals per group and treatment are shown (*p<0.05, **p<0.01,
***p<0.0001).
(A, D) Bar diagrams represent percentages of 2.5mi+CD4+ T cells among total CD4+ T cells
within spleens or MLNs of variously treated NOD.Foxp3EGFP F1 mice.
(B, E) Bar diagrams represent percentages of 2.5mi+Foxp3+ T cells among total CD4+ T
cells within spleens or MLNs of variously treated NOD.Foxp3EGFP F1 mice.
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(C, F) Bar diagrams represent percentages of 2.5mi+Foxp3+ T cells among total 2.5mi+ T
cells within spleens or MLNs of variously treated NOD.Foxp3EGFP F1 mice. For the FACS
analysis, cells were gated on B220−, CD8−, PI− and CD4+ cells.
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FIGURE 6. Th1 and Th2 cytokine analysis in NOD.Foxp3EGFP and NODxB6.Foxp3EGFP F1
mice
Five-to-6-week-old NOD.Foxp3EGFP and NODxB6.Foxp3EGFP F1 females were treated
with 5 doses of 200 μg CTB-2.5mi (A, B and C) or PBS (B and C) every 3 to 4 days i.g.
Four days after the last dose, T cells were analyzed for cytokine production.
(A) Ag-specific 2.5mi+Foxp3− T cells were sorted by FACS directly ex vivo without further
manipulation into a RT-PCR mixture and analyzed for transcription of IFN-γ and IL-4. Left
panels, NODxB6.Foxp3EGFP F1 mice; right panels, NOD.Foxp3EGFP mice; + positive PCR
control using IFN-γ and IL-4 coding DNA plasmid templates, -no template PCR control.
(B) and (C) ELISPOT analysis. Total splenocytes from treated mice were incubated with
100 ng/ml of CTB-2.5mi or CTB and cytokine secretion quantified 2 days later (B, IFN-γ;
C, IL-4). Values indicate spot forming cells (SFC) per 106 splenocytes; mean values ± SEM
are indicated after subtraction of SFC in unstimulated wells. n=6 and 12, resulting from 2
and 4 independent experiments for NOD.Foxp3EGFP and NODxB6.Foxp3EGFP F1 mice,
respectively (*p<0.05, **p<0.01, ***p<0.0001).
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FIGURE 7. Activation and memory markers of 2.5mi+ effector T cells after oral treatment with
CTB-2.5mi in NOD.Foxp3EGFP and NODxB6.Foxp3EGFP F1 mice
NODxB6.Foxp3EGFP F1 (A) and NOD.Foxp3EGFP mice (B) were treated with 5 doses of
200 μg CTB-2.5mi and 4 days after the last dose 2.5mi+Foxp3− T cells from the spleen were
analyzed for CD62L and CD44 expression. Mean values ± SEM of 6 mice per group
analyzed in 2 independents experiments are shown. Naive, CD62Lhi CD44lo; CM (central
memory), CD62Lhi CD44hi; EM (effector memory), CD62Llo CD44hi.
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